Denosumab in men receiving androgen-deprivation therapy for prostate cancer.

Fiche du document

Auteurs
Date

20 août 2009

Type de document
Périmètre
Langue
Identifiants
Source

Serveur académique Lausannois

Relations

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1056/NEJMoa0809003

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/19671656

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1533-4406

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_CBA3A7DE7FAD0

Collection

Serveur Académique Lausannois

Organisation

Université de Lausanne et CHUV

Licences

info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer

Mots-clés 0

Aged; Aged, 80 and over; Androgen Antagonists/adverse effects; Androgen Antagonists/therapeutic use; Antibodies, Monoclonal/adverse effects; Antibodies, Monoclonal/pharmacology; Antibodies, Monoclonal/therapeutic use; Antibodies, Monoclonal, Humanized; Bone Density/drug effects; Bone Density Conservation Agents/adverse effects; Bone Density Conservation Agents/pharmacology; Bone Density Conservation Agents/therapeutic use; Bone Remodeling/drug effects; Denosumab; Double-Blind Method; Fractures, Bone/epidemiology; Fractures, Bone/prevention & control; Gonadotropin-Releasing Hormone/agonists; Humans; Incidence; Injections, Subcutaneous; Lumbar Vertebrae/drug effects; Lumbar Vertebrae/injuries; Lumbar Vertebrae/physiology; Male; Middle Aged; Orchiectomy; Osteoporosis/chemically induced; Osteoporosis/drug therapy; Prostatic Neoplasms/drug therapy; Prostatic Neoplasms/physiopathology; Prostatic Neoplasms/surgery; RANK Ligand/adverse effects; RANK Ligand/pharmacology; RANK Ligand/therapeutic use; Spinal Fractures/epidemiology; Spinal Fractures/prevention & control

Sujets proches En

Therapy Treatments for diseases Medical treatment Therapy Treatment of diseases

Citer ce document

M.R. Smith et al., « Denosumab in men receiving androgen-deprivation therapy for prostate cancer. », Serveur académique Lausannois, ID : 10.1056/NEJMoa0809003

Métriques

Partage / Export

Résumé 0

Androgen-deprivation therapy is well-established for treating prostate cancer but is associated with bone loss and an increased risk of fracture. We investigated the effects of denosumab, a fully human monoclonal antibody against receptor activator of nuclear factor-kappaB ligand, on bone mineral density and fractures in men receiving androgen-deprivation therapy for nonmetastatic prostate cancer. In this double-blind, multicenter study, we randomly assigned patients to receive denosumab at a dose of 60 mg subcutaneously every 6 months or placebo (734 patients in each group). The primary end point was percent change in bone mineral density at the lumbar spine at 24 months. Key secondary end points included percent change in bone mineral densities at the femoral neck and total hip at 24 months and at all three sites at 36 months, as well as incidence of new vertebral fractures. At 24 months, bone mineral density of the lumbar spine had increased by 5.6% in the denosumab group as compared with a loss of 1.0% in the placebo group (P

document thumbnail

Par les mêmes auteurs

Sur les mêmes sujets

Exporter en